Table 3.
Value-based price of gene therapy by modeled country.
| Country | Cost-effectiveness threshold | Pessimistic VBP | Base case VBP | Optimistic VBP | NBS LMIC 1 (25%) | NBS LMIC 2 (50%) | SOC multiplier scenario 1 (0%) | SOC multiplier scenario 2 (10%) | |
|---|---|---|---|---|---|---|---|---|---|
| France | HIC | $55,027 | $302,658 | $875,995 | $2,028,454 | – | – | – | – |
| Germany | $88,043 | $471,324 | $1,365,472 | $3,150,761 | – | – | – | – | |
| Italy | $50,000 | $271,759 | $786,992 | $1,821,407 | – | – | – | – | |
| Spain | $33,016 | $182,227 | $527,076 | $1,221,625 | – | – | – | – | |
| UK | $39,377 | $218,762 | $632,478 | $1,466,318 | – | – | – | – | |
| USA | $100,000 | $538,724 | $1,559,226 | $3,607,440 | – | – | – | – | |
| Ghana | LMIC | $552 | $3073 | $8555 | $18,226 | $8011 | $7667 | $8545 | $8566 |
| India | $397 | $2167 | $6046 | $12,995 | $5714 | $5504 | $6038 | $6054 | |
| Kenya | $483 | $2706 | $7537 | $16,170 | $7124 | $6863 | $7527 | $7548 | |
| Nigeria | $223 | $1112 | $3128 | $6,915 | $3099 | $3081 | $3120 | $3136 | |
| South Africa | $3228 | $17,432 | $48,998 | $105,402 | $46,158 | $44,363 | $3120 | $49,071 | |
| Uganda | $120 | $676 | $1881 | $4,114 | $1824 | $1788 | $48,929 | $1885 | |
| Zambia | $591 | $3070 | $8602 | $18,223 | $8003 | $7625 | $8592 | $8612 |
GTx gene therapy, LMIC low-middle income country, HIC high income country, SOC standard of care, Newborn screening the percentage of the population screened at birth, SOC multiplier the quality of standard of care effect on transition probabilities.
Significant values are in bold.